Jedd Wolchok, MD, PhD

Jedd Wolchok, MD, PhD, FASCO, FAACR, is the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, Director of the PICI Center at Weill Cornell Medicine, and a Professor of Medicine at Weill Cornell College. Dr. Wolchok is a clinician-scientist exploring innovative immunotherapeutic strategies in laboratory models, and a principal investigator in numerous pivotal clinical trials. Dr. Wolchok helped establish immunotherapy as a standard approach to cancer treatment and was instrumental in the clinical development leading to the approval of ipilimumab and the combination of nivolumab and ipilimumab for advanced melanoma. He supervises an NIH R01-funded basic science laboratory which is focused on investigating novel immunotherapeutic agents in pre-clinical laboratory models. The focus of his translational research laboratory is to investigate innovative means to modulate the immune response to cancer as well as to better understand the mechanistic basis for sensitivity and resistance to currently available immunotherapies.

Dr. Wolchok received his BA degree from Princeton University, and his MS, PhD and MD degrees from New York University. Dr. Wolchok has received numerous honors for his work including: American Association for Cancer Research (AACR) Richard and Hinda Rosenthal Memorial Award, the Giants of Cancer Care in Melanoma Award, the Berson Alumni Achievement Award in Clinical and Translational Science and the Zelmanovich Young Alumni Achievement Award from NYU Grossman School of Medicine, the Alfred Taubman Prize for Excellence in Translational Medical Research (Univ of Michigan) and has been designated a Fellow of the American Society of Clinical Oncology (FASCO), as well as board of directors. He has been awarded the Distinguished Alumni Award at MSK, the AACR-Joseph H. Burchenal Award for Outstanding Achievement in Clinical Cancer Research, the ESMO Award for Immuno-Oncology and the David Karnofsky Award from ASCO.

Dr. Wolchok has served on the Board of Directors of ASCO and the Society for Immunotherapy of Cancer (SITC) and currently is the Treasurer of SITC. He is an elected member of American Association for Cancer Research (AACR) board of directors, elected to the AACR academy of fellows (FAACR), the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP) and is Chair of the Melanoma Committee for the ECOG-ACRIN NCI cooperative group. Most recently he has been elected to the National Academy of Medicine (NAM). He is a full member of the Ludwig Institute for Cancer Research.

• New York University School of Medicine, MD
• New York University Graduate School of Arts & Sciences, PhD

• 2016: Alfred Taubman Prize for Excellence in Translational Medical Research
• 2014: American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award; Giants of Cancer Care in Melanoma Award
• 2013: Virginia and Daniel K. Ludwig Chair for Clinical Investigation
• 2012: Melanoma International Foundation's Doctor of the Year award
• 2011: Director, Cancer Vaccine Collaborative
• 2010: Melanoma Research Foundation – Humanitarian Award
• 2008: Damon Runyon-Lilly Clinical Investigator Award